Victoria Johnson

New research reveals significant links between alopecia areata and mental health issues, emphasizing the need for comprehensive care in affected individuals.

Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.

Explore the latest advancements in pulmonology, including FDA approvals and breakthrough therapies for COPD, PAH, and rare respiratory diseases.

KalVista's therapy is now approved under the name Ekterly, the first oral therapy for hereditary angioedema, empowering patients with timely, on-demand treatment options.

Q2 2025 saw new therapies approved for a number of rare disease indications, multiple of which serve as the first disease-modifying therapies in the landscape.

Q2 2025 saw new therapies approved for rare rheumatological conditions and exciting research out of EULAR.

Q2 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

A form of the cytisine regimen, widely used in Eastern Europe for decades, is finally being put in front of US regulators after recently also becoming available in the UK.

Discover how advancements in biologic therapies and precision medicine are transforming asthma and COPD management, enhancing patient care and outcomes.

This recap highlights data on stem cell-derived therapies for type 1 diabetes, cortisol-modulating strategies for hard-to-treat type 2 diabetes, and a novel once-weekly insulin alternative that matches daily injections in efficacy.

Read the latest pivotal data on once-monthly injectables, oral GLP-1 agonists, and novel co-agonist therapies from ADA.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

The FDA approves Lenacapavir, a groundbreaking twice-yearly HIV prevention injection, revolutionizing PrEP options for adults and adolescents.

Explore the latest advancements in biologic therapies for asthma and COPD discussed in a recent clinical forum highlighting personalized medicine and biomarker-driven strategies for improved patient outcomes.

FDA approves the new therapy under the name Enflonsia, offering effective RSV prevention for infants during their first RSV season.

Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.

Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.

New predictive models enhance clinical decision-making for children with pneumonia, identifying severity levels to improve treatment outcomes effectively.

The FDA approves mepolizumab as a new maintenance treatment for COPD, showing significant reduction in exacerbations for specific patients.

The approval adds to Ritestar’s currently approved albuterol sulfate 2.5 mg/3 mL (0.083%), 1.25 mg/3 mL, and 0.63 mg/3 mL strength products.

Associations were particularly strong for people with severe COPD.

Vapendavir shows promise in reducing respiratory symptoms and illness duration in COPD patients infected with rhinovirus.

Long-term studies reveal that benralizumab achieves sustained remission in severe eosinophilic asthma, significantly reducing exacerbations in older adults.

New research follows a previous landmark study that linked mucus plugs to increased mortality in people with COPD even without hallmark symptoms.